Biochemistry and Pharmacology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/214

Filters

2019 1
1
Reset filters

Settings
Statistics
Citations
Start date: 2010 × Author: Ascher, David × Author: Miranda Rodrigues, Carlos Henrique × Author: Denholm, Justin × Author: Dunstan, Sarah ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
    Karmakar, M ; Rodrigues, CHM ; Holt, KE ; Dunstan, SJ ; Denholm, J ; Ascher, DB ; Mokrousov, I (PUBLIC LIBRARY SCIENCE, 2019-05-29)
    Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical data to facilitate reliable and timely identification of genomic determinants of resistance. Here we investigate the structural basis for M. tuberculosis associated bedaquiline resistance in the drug target, AtpE. Together with the 9 previously identified resistance-associated variants in AtpE, 54 non-resistance-associated mutations were identified through comparisons of bedaquiline susceptibility across 23 different mycobacterial species. Computational analysis of the structural and functional consequences of these variants revealed that resistance associated variants were mainly localized at the drug binding site, disrupting key interactions with bedaquiline leading to reduced binding affinity. This was used to train a supervised predictive algorithm, which accurately identified likely resistance mutations (93.3% accuracy). Application of this model to circulating variants present in the Asia-Pacific region suggests that current circulating variants are likely to be susceptible to bedaquiline. We have made this model freely available through a user-friendly web interface called SUSPECT-BDQ, StrUctural Susceptibility PrEdiCTion for bedaquiline (http://biosig.unimelb.edu.au/suspect_bdq/). This tool could be useful for the rapid characterization of novel clinical variants, to help guide the effective use of bedaquiline, and to minimize the spread of clinical resistance.